Literature DB >> 2254635

Criteria of drug-induced liver disorders. Report of an international consensus meeting.

C Bénichou1.   

Abstract

International reporting of adverse drug reactions by pharmaceutical manufacturers to national drug regulatory authorities requires internationally accepted standard definitions of reactions and criteria for assessment of causality. The Council for International Organizations of Medical Sciences (CIOMS) undertook a pilot project to prepare such definitions and criteria, and proposed to use as its model a series of expert consensus meetings organized in France by the pharmaceutical company, Roussel Uclaf, with the participation of the official French network of pharmacovigilance. Under CIOMS auspices, an international meeting was organized to test the feasibility of adapting for international use the outcome of the French consensus meetings on drug-induced liver disorders. The meeting resulted in a series of proposed standard designations of drug-induced liver disorders and criteria of causality assessment.

Entities:  

Mesh:

Year:  1990        PMID: 2254635     DOI: 10.1016/0168-8278(90)90124-a

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  244 in total

1.  Accuracy of hepatic adverse drug reaction reporting in one English health region.

Authors:  G P Aithal; M D Rawlins; C P Day
Journal:  BMJ       Date:  1999-12-11

2.  Hepatotoxicity associated with zolpidem treatment.

Authors:  D Karsenti; P Blanc; Y Bacq; E H Metman
Journal:  BMJ       Date:  1999-05-01

3.  Drug points: prolonged cholestasis associated with irbesartan.

Authors:  R Hariraj; E Stoner; S Jader; D M Preston
Journal:  BMJ       Date:  2000-09-02

4.  Antidepressant-Induced Acute Liver Injury: A Case-Control Study in an Italian Inpatient Population.

Authors:  Carmen Ferrajolo; Cristina Scavone; Monia Donati; Oscar Bortolami; Giovanna Stoppa; Domenico Motola; Alfredo Vannacci; Alessandro Mugelli; Roberto Leone; Annalisa Capuano
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

5.  Cholestatic hepatitis in association with celecoxib. Classification of drug associated liver dysfunction is questionable.

Authors:  Faiyaz Mohammed; Alastair D Smith
Journal:  BMJ       Date:  2002-07-27

6.  A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working group.

Authors:  Michel Sibille; Alain Patat; Henri Caplain; Yves Donazzolo
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

7.  Perfusion CT findings in liver of patients with tumor during chemotherapy.

Authors:  Qing Zhang; Zhen-Guo Yuan; Dao-Qing Wang; Zhi-Hui Yan; Jun Tang; Zuo-Qin Liu
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

8.  Detection of adverse drug reactions in a neurological department: comparison between intensified surveillance and a computer-assisted approach.

Authors:  Petra A Thuermann; Roland Windecker; Joachim Steffen; Markus Schaefer; Ute Tenter; Erich Reese; Hermann Menger; Klaus Schmitt
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 9.  [Morphology of drug induced liver damage].

Authors:  H-U Kasper; U Drebber; I Hirsch; H P Dienes
Journal:  Pathologe       Date:  2006-05       Impact factor: 1.011

10.  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.

Authors:  Naga Chalasani; Robert J Fontana; Herbert L Bonkovsky; Paul B Watkins; Timothy Davern; Jose Serrano; Hongqiu Yang; James Rochon
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.